A New Drug Entirely Designed by AI: 'Time Problem'… AstraZeneca's Roadmap

Artificial intelligence is transforming drug development by revolutionizing how new drug candidates are identified and validated. According to MIT Technology Review, Puja Sapra, AstraZeneca's Chief Executive Officer of R&D Bioengineering and Oncology Target Discovery, explained that AI-driven computational methods have streamlined the entire drug development process from design to analysis. This approach has significantly reduced development timelines while enhancing productivity and innovation. Biotherapeutics are inherently more complex than small-molecule drugs due to their need for precise molecular targeting, stability in the human body, and scalable manufacturing. AstraZeneca employs a 'build-measure-learn' cycle, leveraging AI to prioritize high-potential candidates and focus experimental resources on the most promising leads. This accelerates progress and enables targeting of previously difficult-to-reach biological markers. AI is not only shortening development timelines but also redefining drug design, with next-generation therapies targeting multiple pathways or delivering treatments precisely to specific cell types. Sapra emphasized AI's role in balancing efficacy, safety, and manufacturing feasibility, opening new possibilities for previously untreatable targets. Data remains central to AI competitiveness, with McKinsey estimating that combining generative AI with other computational tools could cut drug discovery timelines by up to 50%. AstraZeneca's competitive edge lies in its proprietary multimodal dataset encompassing molecular structures, binding affinities, safety profiles, and manufacturing outcomes, enabling continuous model refinement and validation.